newsfilter
← Latest News
GlobeNewswire·

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting was accepted.
  • The meeting will take place from February 4–8, 2026, in Savannah, Georgia.
  • Researchers including Christopher Laing, MD, will present data on real-time intravascular pressure measurements using the RenovoCath double-balloon catheter during Trans-Arterial Micro-Perfusion (TAMP) procedures.
  • The study aims to validate a practical method for monitoring intra-arterial pressure to optimize targeted chemotherapy delivery in solid tumors.
  • The presentation is scheduled for Friday, February 6, 2026, at 5:45–6:00 PM ET in the ePoster Corridor (Abstract Number 303).
  • RenovoCath is an FDA-cleared device intended for isolating blood flow & delivering therapeutic agents to peripheral vascular sites, including temporary vessel occlusion.
  • RenovoRx generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025.
  • The company is evaluating its drug-device combination candidate, intra-arterial gemcitabine (IAG), in the ongoing Phase III TIGeR-PaC trial.
  • IAG has received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • RenovoRx continues to actively commercialize RenovoCath & is exploring further revenue opportunities through its own sales efforts or partnerships.